US Pharma MarketingInnovent and Daiichi Sankyo sign deal for Vanflyta in China
Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta, an oral type II FLT3 inhibitor, in China.
Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta, an oral type II FLT3 inhibitor, in China.
Source: Pharmaceutical Technology